Selected article for: "high activity and risk factor"

Author: Fernández-Díaz, Eva; Gracia-Gil, Julia; García-García, Jose Gregorio; Palao, María; Romero-Sánchez, Carlos M; Segura, Tomás
Title: COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
  • Cord-id: un14oynk
  • Document date: 2020_7_17
  • ID: un14oynk
    Snippet: BACKGROUND: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae. CONCLUSION: In selected patients (young, withou
    Document: BACKGROUND: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae. CONCLUSION: In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab.

    Search related documents:
    Co phrase search for related documents